Matauro LLC Invests $1.65 Million in Galapagos NV $GLPG

Matauro LLC acquired a new position in shares of Galapagos NV (NASDAQ:GLPG) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 47,536 shares of the biotechnology company’s stock, valued at approximately $1,647,000.

A number of other hedge funds have also bought and sold shares of GLPG. XTX Topco Ltd bought a new stake in Galapagos during the second quarter valued at $1,114,000. 683 Capital Management LLC lifted its stake in shares of Galapagos by 57.3% in the 1st quarter. 683 Capital Management LLC now owns 110,100 shares of the biotechnology company’s stock valued at $2,766,000 after purchasing an additional 40,100 shares during the period. OLD Mission Capital LLC acquired a new position in shares of Galapagos in the 1st quarter valued at about $1,885,000. Vestal Point Capital LP boosted its position in shares of Galapagos by 11.1% during the 1st quarter. Vestal Point Capital LP now owns 200,000 shares of the biotechnology company’s stock valued at $5,024,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Galapagos during the second quarter worth approximately $261,000. Institutional investors own 32.46% of the company’s stock.

Analyst Upgrades and Downgrades

GLPG has been the topic of several recent analyst reports. Sanford C. Bernstein started coverage on Galapagos in a research note on Wednesday, November 26th. They issued a “hold” rating on the stock. Leerink Partnrs upgraded shares of Galapagos from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada increased their target price on shares of Galapagos from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Friday, November 7th. Leerink Partners set a $40.00 price target on shares of Galapagos and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Finally, Wall Street Zen upgraded shares of Galapagos from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Galapagos has an average rating of “Reduce” and a consensus target price of $31.33.

Galapagos Trading Up 2.1%

Shares of GLPG opened at $32.31 on Friday. The business’s fifty day moving average is $31.72 and its 200 day moving average is $31.51. Galapagos NV has a 12-month low of $22.36 and a 12-month high of $37.78.

Galapagos Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.